- Home
- PFBC vs XERS Comparison
PFBC vs XERS Comparison
Compare PFBC & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFBC | XERS |
|---|---|---|
| Founded | 1991 | 2005 |
| Country | United States | United States |
| Employees | 324 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PFBC | XERS |
|---|---|---|
| Price | $101.61 | $6.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $102.67 | $10.83 |
| AVG Volume (30 Days) | 78.7K | ★ 1.4M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.41% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $2.94 | $34.37 |
| Revenue Next Year | $8.31 | $22.86 |
| P/E Ratio | ★ $8.85 | $693.00 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $79.60 | $4.36 |
| 52 Week High | $103.05 | $10.08 |
Technical Indicators
Market Signals| Indicator | PFBC | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 72.21 | 66.55 |
| Support Level | $92.80 | $6.86 |
| Resistance Level | $103.05 | $7.14 |
| Average True Range (ATR) | 2.19 | 0.25 |
| MACD | 0.75 | 0.08 |
| Stochastic Oscillator | 97.69 | 87.01 |
Price Performance
Historical ComparisonAbout PFBC Preferred Bank
Preferred Bank is a commercial bank located in California. Its products and services are divided into Personal Banking, Business Banking, and Commercial Banking, which include Checking accounts, Savings accounts, CDs, Loans and Credit, Electronic banking, and Treasury Management. It provides personalized deposit services, real estate finance, commercial loans, and trade finance credit facilities to small and mid-sized businesses and their owners, entrepreneurs, real estate developers and investors, professionals, and high-net-worth individuals.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.